Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
91 Cards in this Set
- Front
- Back
Hippocrate |
Cancerous growth=moving crabs |
|
Galen |
Sarcoma
|
|
Necrosis |
Oribaslus
|
|
Lanfran |
Benign and Malignant tumors |
|
Bonetti Terms: Pappilomatosis |
skin elevation
|
|
carcinomatosis |
metastasis
|
|
milliary spread |
distant metastasis |
|
carcinoma dropsy |
malignant ascites |
|
strumatosia |
lymphoma |
|
carcinoids |
small carcinoma. |
|
Recaimer |
coined metastasis |
|
Home |
Characterized leukemia |
|
Lebert |
characterized myeloid tumors |
|
Henry bench jones |
Characterized myeloma |
|
Boveri: |
Did sea urchin experiments
Chromosome affect cancer. |
|
• Cell cycle checkpoint |
o Cells somehow defective o Reacts differently to its surroundings.
|
|
TSG |
o Chromosome that inhibits cell division |
|
Oncogene |
o Chromosome that causes proliferation |
|
malignant progression |
o Benign tumors can progress to malignant tumors |
|
• Clonogenicity |
cancers arise from a single cell |
|
warburg effect |
changes in metabolism |
|
inflammation |
may lead to cancer.
|
|
neoplasm |
new growth |
|
hyperplasia |
increase in size of an organ (physiological, compensatory, pathological) |
|
metaplasia |
adaptive subsititution of one type of adult tissues for another |
|
desmoplasia |
formation and proliferation of connective tissue |
|
dysplasia |
abnorma cellular proliferation, loss of nomrla architechture and orientation |
|
anaplasia |
dedifferentiation of cells. |
|
TGFB |
signals to halt cell cycle, inhibit proliferation, differnetiate, and if needed apoptosis. |
|
matrigel |
see if the cells form tight structures or break off |
|
boyden chamber |
measure chemotactic movement
migrate across membrane |
|
VEGF FGF measurement |
angiogenic factors, used to detect angiogenesis. |
|
Angiogenic Assays |
Clonogenic assay (measure cell survival)
Caspase assay (detects presence of caspase by looking for products of its protease cleavage)
DNA fragmentation (tunel reagent binds to broken up DNA, fluoreseces, like in DNA from apoptosis)
Annexin V (high conserved protein, only on inside due to phosphatidly serine, it flips during apoptosis due to PS switching to the outisde of the membrane) |
|
3 components of epidemiology |
Uncover new etiological lead
Efficacy of preventative measures
Investigate survival predictors |
|
GWAS |
Genome wide association study: looks at tons of markers in the genome to find certain varients that trend to cancer. |
|
5 criteria for cuase effect relationship |
Timing Strength Interaction with other factors prevelance (multiple populations) Plausability |
|
HSC Cell surface markers |
CD34+ CD38- CD59+ CD90+ CD117/Ckit+ lin- |
|
How to characterize leukemia cells |
Morphology Histochemical stains Clel surface markers for flow cytometry Gene expression profiles Karyotype (quantitative and qualitative) |
|
Causes of ALL |
Hyper/hypodiploidy (best, mainly kids) BRC-Abl (bad, main one in adults) MLL rearrangements (bad) |
|
Risk factors of ALL |
Gender (1.3x more male) Younger Higher socioeconomeit In utero radiation Genetic sydrome (like Downs) |
|
Greaves hypothesis |
• Greaves hypothesis, two mutations required. o One in utero, one out of utero.
Patents who don't go to daycare are more likely to get disease. |
|
AML1 ETO |
C8-C21 translocation
Silences AML1 gene. Which is needed for differentiation
needs proliferation mutation too to cause leukemia |
|
Gleevac |
Used to treat CML (ablbcr fusion) pauses cancer, does not kill it. small fraction of genetic mutation wont respond to first gen gleevac, need second gen gleevac.
|
|
3 types of developments |
Observational (hey these people get cancer) empirical (hey this causes cancer in labs) epidemiolocial (hey this population tends to have this disease) |
|
Miller hypothesis |
most if not all chem carcinogens consiste of or can become an electrophile, which reacts with a nucleic acid or protein. |
|
Non miller carcinogens |
nongenotoxic carcinogens. |
|
Friedwald and rous |
Painted mice with 3MC got cancer, initiated cells. added turpentine (chloroplastic agent) or wounding, lead to tumor development. |
|
Murine two stage carcinogenesis protocol |
stage one: put carcinogen dose on back. wait, nothing happens. put a promoter on (continually treat for a while) get papillomas, sometimes get SSC. |
|
Initiator |
genotoxic
initiation creates the genotoxic changes needed for cancer to form. Promotion merely activates those changes. Promotion alone wont cause cancer. Needs to be on initiated cells. |
|
promoter |
nongenotoxic
Nongenotoxic Epigenetic Affect gene regulation, not the genes themselves
They don’t have to be carcinogens on their own. Don’t necessarily cause cancer Complete carcinogens do have promoting activity. Do both promotion and initiation |
|
3 types of common skin cancer in US |
SCC BCC Melanoma |
|
Dosage of carcinogen |
greater dose, more likely cancer. |
|
are carcingens = |
no! |
|
Procarcinogens |
Pro carcinogens are carcinogens that haven’t yet been activated/put into a carcinogen form. P450 and phase 1 phase 2 molecules are used to catabolize molecules in the cell. Lots of factors: location of cells, individual person. Lots of variety. |
|
Phase I and Phase II molecules: |
Phase II enzymes mask the functional group. Conjugate Phase I modify |
|
term that causes differntial sensitivity to things within a species/different species |
polymorphism |
|
why stem cells? |
Live for a long time and are phenotypically vauge. Normally rarely divide. |
|
Protooncogenes, TSG and two stage model |
Protooncogenes and tumor suppressor genes both need to be effected in order for cancer to occur. Need to accumulate a lot of mutations in these both. |
|
Screening and cancer |
Doesn't always save lives, can cause mental stress, detect cancer that isn't fatal, detect cancer early that wouldve been detected later and could have been treated fine. |
|
Tumor cell targets: |
o Growth factors Extracellular matrix Angiogenic pathways o Cell survival pathways • mTor o signaling pathways • Ras, MAPK o Tumor associated antigens • Targets for drugs. o Proteasome |
|
5FU |
block dTMP synthesis by blocking thymidine synthase. dUMP analogue, deletes enzyme activty and can kill stop dna replication. |
|
Bevacizumab |
Binds to VEGF, inhibits it. prevents angiogensies |
|
axtinib |
RTK Binds further down RTK, affet angiogenic growth factors antitumor due to lack of blood vessels and tumor necrosis. |
|
Oxygen and cancer |
Too much or too little. hypoxic areas don't allow drug in. tumor is dormant there. radiation and other drugs need oxygen to work. radiation can kill some cells, which relieves oncotic pressure, and decreases cell tumor size.
blood flow can be viewed by DCE MRI (dynamic contrast mri)
|
|
function of protein interactions |
amongst others, leads to transcription |
|
protooncogenes |
normally promote normal growth mutated, become oncogenes |
|
Vertical Transfer |
MMTV |
|
No oncogene in the virus, but activates an oncogene |
MMTV, Leukemia Viruses |
|
acute transforming tumor retrovisures |
rare, capture genes with oncogenes, need helper virus to replicated, cellular genes might prmote growth of transduced cells
|
|
HIV |
increases cancer by reducing immune system |
|
RNA viruses |
Leukemia viruses I and II HIVI |
|
Oncogene types |
viral and cellular |
|
Mutation leading to RAS oncogene |
GTPase activity inhibition, constituitively bound GTP |
|
CMyc |
• Oncogene • Burkitts lymphoma: csome translocations activate it. • Insertion of retrovirus LTR causes c-myc overexpression • C-myc isn’t altered though, just its expression i.s |
|
Example oncogenes |
Cmyc, Csrc, RAS, BCLT |
|
viral oncogenes |
• Oncogene of viral origins • Vsrc o Viral, can be inserted into cell o Rous sarcoma virus in chicken o Oncogene (not proto) o Related to Csrc, but without activation section. |
|
cellular oncogenes |
• Cellular orgins • C-src. o Protooncogenes. o Can be mutated to be overexpressed or have increased activity. |
|
Somatic mutations |
o Consistent observations, changes in somatic cells. o Burkitts lymphoma • Translocation which activates oncogene o Ras oncogene, put in mic fibroblasts, cause tumors • Causes cancer in humans o Follilculatr lymphomas, • BCL2 oncogene always defregulated by trasnlocations on the gene o Activated human oncogenes cause corresponding tumors in transgenic mice. • Genes mutate in human cancer, make transgenic mice, causes cancer. |
|
Oncogenes |
o Promote proliferation o Dominant, highly conserved o Types • Viral • Cellular |
|
TF |
trasncription facotr: regulate genes, increase/decrease expression, incresae and decrease oncogene transcription |
|
Chromatin remodelers |
move chromatin, effect expression epigenetically |
|
growth factors |
• Auto and paracrine • Too much growth factor, increases growth. • Changes in receptors that are responsible for carrying signals. • Change in receptor, change in signaling |
|
cell cycle regulators |
regulate cell cycle! haha |
|
apoptosis regulators |
cell s must die, if disrupted they wont, if they survive they can become cancerous. |
|
TSG Concept |
• Brief concept: o Can go over full lecture, possibly add something: we’ll summarize later in the lecture. • A type of gene that makes a protein called tumor suppressor protein that helps control cell growth. Mutations (changes in DNA) in tumor suppressor genes may lead to cancer. o AKA anti-oncogene. |
|
TSG examples |
Rb, P53, APC, BRCA1/2, (read notes on all) |
|
Mechanisms of TSGs |
And what TSG does what |
|
Supression of cell division |
APC, Rb, P53, P21 |
|
Induction of apoptosis |
APC, P53, FasR, pTen |
|
DNA damage repair |
FA/BRCA, P53 |
|
Inhibition of metastasis |
metastatin |